Why Ag-Input Companies Fail at In-House Fermentation (And How CDMOs Fix It)
The demand for stable, safe and effective biological ag inputs has been largely accelerated by the need to reduce the negative effects of climate change, occurrences of invasive pests and pesticide-resistant organisms, soil fertility decline, and also by the surging consumer demand for nutritious, sustainably produced food. For ag-input companies, this represents a massive opportunity—and a significant manufacturing challenge.
While many innovators consider bringing microbial fermentation in-house for perceived control and cost savings, the reality often leads to stalled projects and sunk costs. Commercial-scale fermentation is a discipline that requires precision engineering, deep process knowledge, and CAPEX-heavy infrastructure.
This article explores why in-house agricultural biologicals production often fails and how partnering with a specialized fermentation CDMO derisks the path to market.
The Core Challenge: Consistency
Unlike chemicals, living microbes are inherently variable. Strains must remain genetically stable, survive industrial fermentation stress, and maintain viability during downstream formulation, storage, and field application. A single deviation in the production parameters can shift product performance dramatically. Farmers, however, demand reproducibility and every bag or bottle must perform identically, regardless of soil type or season. This variability makes agricultural fermentation uniquely challenging compared to pharmaceuticals or food fermentation. Achieving consistency requires a high level of bioprocess control, stringent quality control, tailored downstream processing approaches, and experience with strain-specific idiosyncrasies – all of which are difficult for newcomers to build from scratch.
Why In-House Fermentation Fails
The motivations for building internal fermentation capacity are understandable – cost-per-unit control reduces the perceived dependency on contract manufacturing; IP is kept under one roof, and operational agility eases product development. But scaling up is not a linear process. The leap from 1 L bench-top bioreactors to 10,000 L commercial production involves layers of complexity in mass transfer, contamination control, automation, and regulatory compliance. Without mature infrastructure and experienced bioprocess professionals, in-house operations often fail to deliver on their promises. The biggest risks are related to costs, knowledge gaps, scale-up issues and quality control.
1. CAPEX & Hidden Costs
A common misconception is that the main costs of fermentation operations include staff, rent, lab equipment, bioreactors, and supporting machinery. To have a fully operational fermentation facility, it is necessary to continuously invest in utility upgrades (sterile air, water-for-injection, waste treatment, etc.), automated systems for monitoring and control, and regulatory compliance certifications.
What might seem like a one-time investment can quickly turn into a continuous drain on capital and operational budgets. Industry benchmarks show that a 10,000 L facility can easily exceed $30–50 million in upfront investment, with annual operational costs often 2–3x higher than expected due to utilities, maintenance, and quality control overhead.
2. Knowledge Gaps
Running a successful fermentation operation relies on deep, cross-disciplinary expertise in microbiology, process engineering, and bioprocess optimization. Finding experts with such specific interests, especially those with hands-on experience in bioprocess development and scale-up, is not an easy feat. Underestimating the talent required to support large-scale fermentation operations often leads to costly inefficiencies, inconsistent product performance, and stalled projects.
3. Scale Up Issues
What might work in a shake flask, often fails in a 10,000L bioreactor. Process control is a completely different game at bench and commercial scale, as the large biomass volume creates challenges in oxygen transfer, mixing, and keeping everything free of contamination. Without experienced scale-up engineers, companies can spend years troubleshooting and still fall short of commercial volumes.
4. Quality Control (QC)
Consistency is a must in agriculture. Farmers and distributors expect the same performance from every product batch, being used to the stability of synthetic chemicals. Biologicals are far more sensitive to conditions faced during production and in the field, requiring rigorous quality control pipelines covering strain stability, contamination testing, and product potency. This adds another layer of cost and complexity that many companies have trouble handling.
How the CDMO Model Solves This
Contract Development and Manufacturing Organization (CDMO) model is designed to neutralize the exact risks that set back in-house fermentation projects, and turn prospective products into commercial successes.
Unlike ag-input companies, which typically focus on product discovery, formulation, and market deployment, CDMOs specialize in bioprocess development and production at scale. Their advantages span infrastructure, expertise, operations, and risk management. Instead of reinventing the wheel, ag-input companies can leverage infrastructure and expertise already optimized for success. For many, this is the difference between a delayed, over-budget product launch and a competitive market entry.
With established infrastructure, teams of seasoned specialists and validated manufacturing technologies, CDMOs increase speed-to-market and eliminate the burden of long-term CAPEX and operational overhead.
When Does In-House Make Sense?
In-house fermentation can still be viable under specific conditions:
- The company has a mature product line with consistent, predictable demand.
- Volumes are high enough to justify investment in a dedicated facility.
- A strategic advantage exists in owning production (e.g., proprietary technology or supply security).
For most ag-input innovators, however, partnering with a CDMO during development and scale-up ensures faster, more reliable, and less risky market entry. In many cases, CDMOs remain the long-term solution for derisking production – even after products reach commercial scale.
Focus on Your Innovation, Let Us Master the Manufacturing
Building a successful microbial fermentation operation is about more than “biology and steel”—it’s about deep, specialized expertise. While the allure of in-house control is strong, the hidden complexities often hinder innovation and drain resources.
The strategic alternative is to partner with a CDMO that speaks your language. At Evologic Technologies, we specialize in fermentation and technical formulation specifically for the agri-tech industry. We provide the infrastructure, expertise, and quality systems to transform your promising strain into a stable, effective, and commercially successful product. Ready to de-risk your production scale-up?